Atlas Trials

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

Clinical trial NCT02683941 · TERMINATED

Trial details

NCT number
NCT02683941
Sponsor
Ipsen
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Neuroendocrine Tumors in Lung
Start date
2017-03-06
Primary completion
2020-02-28
Enrollment
77

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.